Search the Newsreel

Cineverse Reports First Quarter Fiscal Year 2027 Results

Cineverse Corp. announced strong first-quarter fiscal year 2027 results, with revenue reaching $30.6 million, a 175% increase driven by recent technology acquisitions. The company reported adjusted EBITDA of $0.5 million, a $2.6 million improvement, and highlighted 4.5 billion minutes streamed, marking its most-watched streaming …

National CineMedia to Acquire Captivate for $275M to Create Leading Premium Video and Digital Out-of-Home Advertising Platform

National CineMedia (NCM) has announced its acquisition of Captivate Holdings, LLC for $275 million, aiming to create a leading premium video and digital out-of-home advertising platform. This merger will combine NCM's cinema advertising with Captivate's digital video elevator and lobby advertising network, expanding their …

Generate Biomedicines (GENB) Stock Price, News & Analysis

Generate Biomedicines (NASDAQ: GENB) utilizes machine learning and generative AI for novel therapeutic design and discovery. The company recently reported Q2 2026 earnings, missing analyst estimates, and has a "Moderate Buy" consensus rating with a price target of $25.40, suggesting a 62.4% upside. Its …

embracing future holdings ltd Earnings dates

Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake

Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which …

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

Dun & Bradstreet, Inc. And nCino, Inc. Collaborate To Speed Client Onboarding And Enhance Lifecycle Management For Financial Institutions

Dun & Bradstreet and nCino have announced a strategic alliance to integrate D&B's verified business identity and risk context into nCino's Client Lifecycle Management solution. This collaboration aims to automate client onboarding and enhance ongoing monitoring for financial institutions by connecting D&B's Commercial Graph …

nCino and Dun & Bradstreet Partner to Automate Commercial Onboarding and KYC Monitoring

nCino and Dun & Bradstreet have announced a partnership aimed at automating commercial onboarding and Know Your Customer (KYC) monitoring processes. This collaboration seeks to streamline financial institution operations by integrating Dun & Bradstreet's data and analytics into nCino's platform.

China Cinda Asset Management (SEHK:1359) Cuts Profit Guidance, Is The Premium Valuation Justified?

Strategic Play: D. Brock Denton Acquires Cintas Stock Options To Portfolio Worth $8K

D. Brock Denton, EVP at Cintas (NASDAQ: CTAS), recently acquired stock options for 22,434 shares, valued at approximately $8,300. This insider transaction suggests a positive outlook for the company's stock, though financial indicators like debt-to-equity ratio and revenue growth should also be considered by …

NCNO|nCino Inc|Price:19.305|Chg%:+0.305

Cincinnati Financial Corporatio (CINF) Stock forecasts

Argus has lowered its target price for Cincinnati Financial Corp (CINF) to $191.00. The company, a property and casualty insurer, currently has a stock price of $172.70. This report was published on August 12, 2026.

nCino and Dun & Bradstreet Collaborate to Speed Client Onboarding and Enhance Lifecycle Management for Financial Institutions

New integration brings the D&B Commercial Graph to the nCino Platform, giving institutions access to D&B verified business identity and risk context within the workflows they use every day JACKSONVILLE, Fla. and WILMINGTON, N.C., Aug. 13, 2026 /PRNewswire/ -- Dun & Bradstreet and nCino …

Form 8K Cingulate Inc For: 13 August By Investing.com

This article reports that Cingulate Inc. filed a Form 8K on August 13. The filing is brief and does not provide specific details about the content of the Form 8K. It notes that the information

Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary

Cingulate Inc. reported its Q2 2026 financial results, showing no product revenue and a net loss of $5.87 million, an increase from $4.98 million in the prior-year quarter. Key business developments include receiving an FDA complete response letter for CTx-1301 requesting additional CMC data, …

Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash

Cingulate Inc. reported a net loss of $5.9 million for the second quarter of 2026, with cash and cash equivalents totaling $28.4 million. The company is preparing for a resubmission of its CTx-1301 ADHD treatment NDA following an FDA Complete Response Letter. Cingulate anticipates …

Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter

Cingulate reported its second-quarter 2026 financial results, showing $28.4 million in cash and cash equivalents and a net loss of $5.9 million. The company expects its cash runway to extend into mid-2027 as it progresses with NDA resubmission work for CTx-1301 and builds commercial …

Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug

Cingulate Inc. (NASDAQ:CING) reported a net loss of $5.9 million for Q2 2026 and announced plans to resubmit its New Drug Application for CTx-1301, an ADHD treatment, after receiving a Complete Response Letter from the FDA requesting additional chemistry, manufacturing, and controls information. The …

Cingulate’s ADHD Drug Patent Protects Its Formulation Through 2042

Cingulate Inc. reported its second-quarter 2026 financial results, highlighting $28.4 million in cash and cash equivalents, expected to fund operations into mid-2027. The company is advancing its CTx-1301 ADHD drug toward NDA resubmission following an FDA Complete Response Letter and secured a new U.S. …

Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cintas stock holds above $200 as analysts see limited upside

Cintas stock is trading just above $200, with analysts projecting a modest 4.32% upside from current levels to a 12-month target of $212.31. Despite strong double-digit earnings and high single-digit revenue growth forecasts, the stock's performance has been more muted, suggesting much of the …

Cinemark Holdings Inc to Issue Quarterly Dividend of $0.09 (NYSE:CNK)

Cinemark Holdings Inc (NYSE:CNK) has declared a quarterly dividend of $0.09

National CineMedia (NASDAQ:NCMI) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded National CineMedia (NASDAQ:NCMI) to a "strong sell" rating, contributing to a mixed analyst outlook for the company. This downgrade comes after National CineMedia reported a quarterly loss of $0.10 per share, missing estimates, and revenue that also fell short of …

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

Parabilis Medicines reported a narrower Q2 net loss of $2.32 per share, with revenue reaching $148,000. Following this news, the company's shares experienced a rise in pre-bell trading. Parabilis Medicines, formerly FOG Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing transformative medicines for …

Parabilis Medicines: Q2 Earnings Snapshot

PARABILIS MEDICINES (PBLS) Stock News & Updates

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines reported its second quarter 2026 financial results, highlighting significant progress in advancing zolucatetide for Wnt/β-catenin-driven diseases and expanding its Helicon™ platform through a collaboration with Regeneron. The company ended the quarter with a strong financial position of $1.1 billion in cash, cash …

Cintas Corporation $CTAS Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB has reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 5.7% in Q2, selling 7,036 shares but still holding 117,263 shares worth $19.9 million. This comes as Cintas reported strong quarterly earnings, beating expectations with an EPS of $1.29 and revenue of …

BeOne Medicines Grants New RSUs to Staff and Service Provider Under Incentive Plan

Cintas Corporation $CTAS Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. significantly reduced its stake in Cintas Corporation ($CTAS) by 56.6% in Q2, selling 8,772 shares. Despite this, Cintas has shown strong financial performance, beating EPS estimates, increasing revenue, and raising its quarterly dividend. The company maintains a "Moderate …

Sei Investments Co. Takes Position in Disc Medicine, Inc. $IRON

Sei Investments Co. has initiated a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 15,510 shares valued at approximately $992,000. Institutional investors now collectively own 83.70% of the company, while insiders have recently sold over 110,000 shares worth around $8 million. Disc Medicine exceeded …

Cinemark Holdings Inc $CNK Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly increased its stake in Cinemark Holdings Inc (NYSE:CNK) by 378.4% in the second quarter, now holding 117,150 shares valued at approximately $3.7 million. Several other institutional investors also expanded their positions. Cinemark shares rose 2.0% to $37.38 and reported …

Cincinnati Financial (NASDAQ:CINF) Shares Pass Above 200 Day Moving Average - Here's What Happened

Cintas Corp (CTAS) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

PVR INOX vs Cineline India: Share Price, PE and ROE Compared

Cinemark Holdings, Inc. Elects Lawrence Burian as A Class II Director, Effective August 12, 2026

Cinemark Holdings, Inc. announced the election of Lawrence Burian as a Class II director, effective August 12, 2026, expanding its Board to 12 members for succession planning. Burian, 56, brings over three decades of leadership experience in sports, media, and entertainment, with expertise in …